t
| Date | 4 Jun 2024 |
| Time | 08:00:00 |
| Category | Capital structure |
| ID | 9398Q |
|
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") |
||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||
|
COMPANY NAME: |
||||||||||||||||||||||||||||||||||||||||
|
AOTI, Inc.
|
||||||||||||||||||||||||||||||||||||||||
|
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : |
||||||||||||||||||||||||||||||||||||||||
|
Principal place of business: 3512 Seagate Way Suite 100 Oceanside, CA 92056 United States of America
Registered address: 7901 4th St N STE 300 St. Petersburg, FL 33702 United States of America
|
||||||||||||||||||||||||||||||||||||||||
|
COUNTRY OF INCORPORATION: |
||||||||||||||||||||||||||||||||||||||||
|
United States of America
|
||||||||||||||||||||||||||||||||||||||||
|
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: |
||||||||||||||||||||||||||||||||||||||||
|
https://aotinc.net
|
||||||||||||||||||||||||||||||||||||||||
|
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: |
||||||||||||||||||||||||||||||||||||||||
|
Company business: Medical technology group with a proprietary therapy for the reduction in hospitalisations and amputations caused by non-healing wounds, particularly diabetic foot ulcers.
Main country of operations: United States of America
|
||||||||||||||||||||||||||||||||||||||||
|
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): |
||||||||||||||||||||||||||||||||||||||||
|
Details of securities: TBC common shares with par value of US$0.00001 per share
Transfer restrictions: Regulation S, Category 3
Issue price: TBC
Treasury shares: nil
|
||||||||||||||||||||||||||||||||||||||||
|
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: |
||||||||||||||||||||||||||||||||||||||||
|
Capital raise (primary): c. US$25 million Capital raise (secondary): TBC Market capitalisation on Admission: TBC
|
||||||||||||||||||||||||||||||||||||||||
|
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: |
||||||||||||||||||||||||||||||||||||||||
|
TBC
|
||||||||||||||||||||||||||||||||||||||||
|
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: |
||||||||||||||||||||||||||||||||||||||||
|
None
|
||||||||||||||||||||||||||||||||||||||||
|
THE COMPANY HAS APPLIED FOR THE VOLUNTARY CARBON MARKET DESIGNATION (Y/N) |
||||||||||||||||||||||||||||||||||||||||
|
N
|
||||||||||||||||||||||||||||||||||||||||
|
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): |
||||||||||||||||||||||||||||||||||||||||
|
Dr. Michael (Mike) Stephen Griffiths - Chief Executive Officer Anthony Matthew Moffatt - Chief Operating Officer Jayesh Pankhania - Chief Financial Officer Douglas William Frederick Le Fort - Non-Executive Chairman Anthony (Tony) Rhys Bourne - Non-Executive Director Dr. Ceri Elizabeth Morgan - Non-Executive Director Richard John Cotton - Senior Independent Director
|
||||||||||||||||||||||||||||||||||||||||
|
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): |
||||||||||||||||||||||||||||||||||||||||
*Mike Griffiths, CEO, is a beneficiary and trustee of the Griffiths Family Trust
|
||||||||||||||||||||||||||||||||||||||||
|
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: |
||||||||||||||||||||||||||||||||||||||||
|
American Diabetes Association Society for Vascular Surgery Foundation
|
||||||||||||||||||||||||||||||||||||||||
|
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: |
||||||||||||||||||||||||||||||||||||||||
|
(i) 31 December (ii) 31 December 2023 (iii) See below:
HY24 - 30 September 2024 FY24 - 30 June 2025 HY25 - 30 September 2025
|
||||||||||||||||||||||||||||||||||||||||
|
EXPECTED ADMISSION DATE: |
||||||||||||||||||||||||||||||||||||||||
|
18 June 2024
|
||||||||||||||||||||||||||||||||||||||||
|
NAME AND ADDRESS OF NOMINATED ADVISER: |
||||||||||||||||||||||||||||||||||||||||
|
Peel Hunt LLP 7th Floor, 100 Liverpool Street London EC2M 2AT
|
||||||||||||||||||||||||||||||||||||||||
|
NAME AND ADDRESS OF BROKER: |
||||||||||||||||||||||||||||||||||||||||
|
Peel Hunt LLP 7th Floor, 100 Liverpool Street London EC2M 2AT
|
||||||||||||||||||||||||||||||||||||||||
|
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: |
||||||||||||||||||||||||||||||||||||||||
|
https://aotinc.net
|
||||||||||||||||||||||||||||||||||||||||
|
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY |
||||||||||||||||||||||||||||||||||||||||
|
QCA
|
||||||||||||||||||||||||||||||||||||||||
|
DATE OF NOTIFICATION: |
||||||||||||||||||||||||||||||||||||||||
|
4 June 2024
|
||||||||||||||||||||||||||||||||||||||||
|
NEW/ UPDATE: |
||||||||||||||||||||||||||||||||||||||||
|
NEW
|
||||||||||||||||||||||||||||||||||||||||